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Biological Systems Engineering, University of Nebraska‐Lincoln, P.O. Box 830726, Lincoln, 
Nebraska, 68583-0726
Abstract
Pain originating from an intervertebral disc (discogenic pain) is a major source of chronic low 
back pain. Pathological innervation of the disc by pain‐sensing nerve fibers is thought to be a key 
component of discogenic pain, so treatment with biomaterials that have the ability to inhibit 
neurite growth will greatly benefit novel disc therapeutics. Currently, disc therapeutic biomaterials 
are rarely screened for their ability to modulate nerve growth, mainly due to a lack of models to 
screen neuromodulation. To address this deficit, our lab has engineered a three dimensional in 
vitro disc innervation model that mimics the interface between primary sensory nerves and the 
intervertebral disc. Further, herein we have demonstrated the utility of this model to screen the 
efficacy of chondroitin sulfate biomaterials to inhibit nerve fiber invasion into the model disc. 
Biomaterials containing chondroitin‐4‐sulfate (CS‐A) decrease neurite growth in a uniform gel 
and at an interface between a growth‐permissive and a growth‐inhibitory gel, while chondroitin‐6‐
sulfate (CS‐C) is less neuroinhibitory. This in vitro model holds great potential for screening 
inhibitors of nerve fiber growth to further improve intervertebral disc replacements and 
therapeutics.
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Chronic low back pain (LBP) is a major cause of disability, healthcare costs, and decreased 
quality of life.1,2 All age groups are affected by chronic LBP, and it is a global epidemic 
with a lifetime prevalence of 38.9% and increased severity in older populations.3,4 An 
estimated 26–42% of chronic LBP cases are due to pain originating within the intervertebral 
disc, which is termed disc-associated or discogenic LBP.5–7 Current treatments for 
discogenic pain include long‐term pain medication, physical therapy, semi‐invasive 
treatments such as anti‐inflammatory injections, and surgeries such as spinal fusions; 
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however, these options have limited efficacy for most patients.8–11 Therefore, alternative 
treatments for chronic discogenic LBP are needed.
Developing new treatments for discogenic LBP requires a mechanistic understanding of its 
causes, which are closely tied to changes in the disc that occur during disc degeneration. The 
disc is composed of an outer lamellar ring, the annulus fibrosus (AF), and an inner core 
called the nucleus pulposus (NP). The NP contains high amounts of chondroitin sulfate 
proteoglycans (CSPGs) such as aggrecan that maintain the water content of the disc and 
inhibit nerve growth and vascularization.12,13 The healthy disc is predominantly aneural and 
avascular, with nerve fibers (i.e., neurites) and blood vessels limited to the outer edges of the 
AF. During disc degeneration, the matrix of the disc degrades and the concentration of 
CSPGs decreases, the disc loses water content and height, and other disruptions such as 
annular fissures occur.8,14 The reduction in CSPG‐rich neuroinhibitory matrix combines 
with degenerate disc cell secretion of neurotrophic factors (e.g., NGF and BDNF) and 
proangiogenic factors (e.g., VEGF) to promote sensory neurite and blood vessel growth into 
the disc.8,15,16 Once the disc has become innervated with pain‐sensing (nociceptive) 
neurites, the nerve endings may be directly stimulated by inflammatory factors, irritants, or 
growth factors secreted by disc cells.8,15 Sensory neurites stimulated by the harsh 
microenvironment within the degenerate disc are the proposed source of discogenic pain.8,15
Clinical evidence from patients with disc degeneration and LBP further supports the role of 
disc innervation in discogenic pain. For example, in one study 68% of 61 human degenerate 
discs were innervated.17 Many researchers have found evidence of nociceptive neurite 
markers deep within discs (sometimes extending into the NP) of patients with LBP.18–22 
Specifically, markers of pain sensation such as substance P and calcitonin gene‐related 
peptide (CGRP) are found in the majority of the neurites identified in degenerate, painful 
discs.22 Additionally, recent evidence of innervation in discogenic neck pain supports a 
similar mechanism for discogenic LBP.23,24 Induced and age‐related disc degeneration in 
mouse and rat models have also exhibited increased disc innervation, including into the NP.
25–28
 These data demonstrate a strong link between disc degeneration, increased disc 
innervation, and discogenic pain.
Despite the strong association between disc innervation and discogenic pain, current 
biomaterials for disc regeneration are often characterized with the disc environment in mind 
but without direct examination of the effects on sensory neurite growth.29,30 This is due to a 
lack of in vitro models that mimic the conditions of pathological disc innervation where 
sensory nerves sprout through the AF into the NP. Current models of neuroinhibition often 
utilize two‐dimensional (2D) cultures of sensory neurons on a neuroinhibitory 
substrate12,31,32 or single component hydrogels33 which do not adequately mimic the 
complex disc environment. Previous in vitro research of the behavior of neurites at a 3D 
interface was limited to a glial scar model utilizing embryonic chick dorsal root ganglia 
(DRG), which is not representative of pathologic disc innervation because the gel contents 
are not similar to the disc.34 Here, we present a novel model that mimics pathologic 
innervation in the disc by creating an interface between a nerve growth‐permissive hydrogel 
and a disc‐like gel to screen neuroinhibitory properties of specific materials (Fig. 1).
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The initial candidate materials chosen for assessment with our in vitro disc innervation 
model were chondroitin sulfate (CS) biomaterials as there is a robust connection between 
increased disc innervation and the reduction of neuroinhibitory CSPGs that occurs with age 
and disc degeneration.12,13,35 The neuroinhibitory properties of CSPGs are determined by 
the different sulfation patterns of the CS the CSPGs contain because the sulfation pattern 
determines the neuronal receptors to which the CS can bind.36–38 In bovine aggrecan, the 
main sulfation patterns are 62.3% chondroitin‐4‐sulfate (CS‐A; Fig. 1A), 25% chondroitin‐
6‐sulfate (CS‐C; Fig. 1B), and 12.7% unsulfated chondroitin.33 Human aggrecan from 
articular sources also consists mainly of CS‐A and CS‐C, with the ratio between the two 
varying with age and location in the tissue.39 Interestingly, the effects of CS‐A and CS‐C 
can range from strongly neuroinhibitory to not neuroinhibitory at all depending on the 
species and neuronal cell type investigated (mouse, rat, or chicken; cerebellar granule 
neuron, cortical neuron, or DRG neuron).31,33,34,40,41 To maximize relevance to disc 
physiology, CS‐A and CS‐C were chosen as potential neuroinhibitory biomaterials for 
screening in our model.
The goals of this work were to (i) engineer a culture model to mimic sensory neurite growth 
into an intervertebral disc and (ii) screen CS biomaterials for rat DRG neuroinhibition. The 
hypothesis of this study was that CS‐A and CS‐C would inhibit neurite growth of neonatal 
rat DRGs in hydrogel culture. The neuroinhibitory properties of CS‐A and CS‐C 
biomaterials were first assessed in 3D uniform composition hydrogels, demonstrating that 
CS‐A was more strongly neuroinhibitory than CS‐C. The in vitro disc innervation model 
assessing neuroinhibition at the interface of two different gels then established that CS‐A is 
neuroinhibitory at an interface, and enzymatic digestion of the CS‐A significantly decreased 
the neuroinhibition thereby verifying that CS is necessary for neuroinhibition. Together, 
these results demonstrate we have established an in vitro innervation model capable of 
screening neuroinhibitory properties of biomaterials and that CS‐A is an effective 
neuroinhibitory biomaterial with potential uses in disc biomaterials.
METHODS
Fabrication and Characterization of Methacrylated Biomaterials
Biomaterial Synthesis—Hyaluronic acid (HA, 53747; MilliporeSigma, St. Louis, MO) 
was the control scaffold because HA is prevalent in disc extracellular matrix and does not 
modulate neurite growth. Chondroitin sulfate A from bovine trachea (CS‐A, C6737; 
MilliporeSigma) and chondroitin sulfate C from shark cartilage (C4384; MilliporeSigma) 
were the neuroinhibitory molecules screened (Fig. 1A and B). Methacrylic anhydride 
(276685; MilliporeSigma) groups were added to the backbone molecules (HA, CS‐A, or 
CS‐C) according to published methods42,43 to permit UV‐photo‐ initiated polymerization of 
the methacrylated biomaterials (designated by MA prefix) MAHA, MACS‐A, or MACS‐C 
(Fig. 1D). Methacrylation: 0.5 g HA, 2.5 g CS‐A, or 2.5 g CS‐C in ultrapure water reacted 
with excess MA (1.895 ml for HA, 10 ml for CS‐A or CS‐C) at 4°C with NaOH pH 
adjustment to 8. Each compound was precipitated twice in ethanol (MAHA) or once in 
acetone (MACS‐A, MACS‐C), dialyzed for 3 days using a 10 MW cassette (87733; Thermo 
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Fisher Scientific, Waltham, MA), and lyophilized (710401000; Labconco, Kansas City, 
MO).
Nuclear Magnetic Resonance (NMR) Spectroscopy Characterization of 
Biomaterials—NMR was used to characterize the degree of methacrylation. Samples were 
dissolved in deuterium oxide (1133660100; MilliporeSigma) at 2 mg/ml for MAHA and 10 
mg/ml for MACS‐A and MACS‐C. Proton NMR spectroscopy was performed (Avance III‐
HD 700 MHz spectrometer; Bruker, Billerica, MA) in the University of Nebraska‐Lincoln 
Research Instrumentation Facility. Degree of methacrylation was the ratio of the 
methacrylate peak integral at ~1.8 ppm to the HA/CS carbohydrate peak integral at ~1.9 
ppm.42,44 The NMR peaks created by methacrylation were identified by comparison with 
the NMR spectra for unmethacrylated HA/CS (data not shown) and also by referencing 
published peak locations.42,44
Base Hydrogel Composition
All culture experiments utilized the following biomaterial combinations: (i) MAHA at 2.50 
mg/ml, (ii) MAHA at 2.25 mg/ml plus MACS‐A at 10 mg/ml, or (iii) MAHA at 2.25 mg/ml 
plus MACS‐C at 10 mg/ml. All hydrogels contained the following components: type I 
collagen at 2.25 mg/ml, 0.3% Irgacure (2‐Hydroxy‐4′ (2‐hydroxyethoxy)‐2‐
methylpropiophenone; 410896; MilliporeSigma), 1× DMEM (D2429; MilliporeSigma), 250 
mM HEPES (H0887; MilliporeSigma), and 138 mM sodium bicarbonate (S6014; 
MilliporeSigma). First, Irgacure was dissolved in concentrated DMEM/HEPES/sodium 
bicarbonate solution, and then methacrylated biomaterials (MAHA, MACS‐A, and MACS‐
C) were added and dissolved for 2 days at room temperature in the dark with agitation. The 
day of gel fabrication, 1× phosphate‐buffered saline (PBS) and type I collagen (354249; 
Corning Inc., Corning, NY) were added on ice.
Mechanical Characterization
The base hydrogel mixtures were injected from a syringe with a 23‐gauge needle into an 8 
mm diameter silicone mold (666305; Grace BioLabs, Bend, OR) sandwiched between glass 
slides. Slides were then subjected to thermal gelation for 30 min at 37°C followed by 2.5 
min of UV‐photo‐initiated cross‐linking on each side of the mold. Hydrogels were removed 
from the molds and kept in 1× PBS overnight at 4°C before rheology. Porcine NP tissue 
punches (8 mm diameter) were also characterized. Porcine cervical spines were obtained 
through a material transfer agreement with the United States Meat Animal Research Center 
(USMARC, USDA ARS). Intact NPs were isolated and a punch biopsy tool (501181245; 
Thermo Fisher Scientific) used to create a cylinder of NP tissue. Viscoelastic properties 
(storage and loss moduli) of the hydrogel samples and NP tissue punches were measured 
using oscillatory rheology with a frequency sweep from 0.1 to 1.0 rad/s on a rheometer 
(MCR 302; Anton Paar, Graz, Austria).
Cytocompatibility of Hydrogels with NP Cells
Human NP Cell Culture—Commercially available human NP cells (4800; ScienCell, 
Carlsbad, CA) were expanded in complete NP media (4801; ScienCell) in a T75 flask coated 
with poly‐L‐lysine (413; Scien-Cell) at 37°C in hypoxic conditions (3.5% O2, 10% CO2, 
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86.5% N2) using a hypoxia chamber (27310; StemCell Technologies, Vancouver, Canada). 
After expansion, cells were trypsinized (25200056; Thermo Fisher Scientific), counted, and 
resuspended in cold 1× PBS for incorporation into hydrogels at a seeding density of 1.5 
million cells/ml. Cells were mixed with the base hydrogel described above, and 150 μl 
pipetted into 48‐well plate prior to thermal gelation (30 min at 37°C) followed by UV‐
photo‐initiated cross‐linking (90 s). Gels were cultured with 300 μl complete NP media at 
37°C in normoxic conditions.
Metabolic Activity Assessment—NP cell populations embedded in hydrogels were 
evaluated using an alamarBlue assay (88951; Thermo Fisher Scientific) according to the 
manufacturer’s instructions on days 1, 4, and 7 of culture. Media absorbance at 570 and 600 
nm was measured using a microplate reader (Synergy H1; BioTek, Winooski, VT) and the 
percent of alamarBlue reduction calculated.
Cell Viability—At the end of 7 days of culture, the proportion of living and dead NP cells 
in selected samples were determined using a LIVE/DEAD® Viability/Cytotoxicity Kit 
(L3224; Thermo Fisher Scientific) according to manufacturer’s instructions with 2 μM 
calcein AM and 4 μM EthD‐1 for 20–30 min. Cells were imaged on a confocal laser 
scanning microscope (LSM 800; Carl Zeiss Microimaging, Inc., Jena, Germany) on a single 
plane 60 μm below the gel surface at three distinct x–y locations in each gel using excitation 
at 488 nm for calcein AM and 561 nm for EthD‐1. Quantification was performed using the 
Zen Blue 3.0 Image Analysis software (Carl Zeiss Microimaging, Inc.).
Dorsal Root Ganglion Culture
Neonatal Rat DRGs—All animal experiments were performed in accordance with the 
Guide for the Care and Use of Laboratory Animals and approved through the University of 
Nebraska‐Lincoln’s Institutional Animal Care and Use Committee. Sprague–Dawley rats 
aged postnatal days 0–3 were euthanized and DRGs were removed by sterile dissection (Fig. 
1C), placed in cold Neurobasal media (21103049; Thermo Fisher Scientific), nerve roots 
trimmed to remove all pre‐existing neurites outside of the DRG, and body of the DRG cut 
into two pieces prior to hydrogel embedding a single DRG piece per gel. For larger DRGs, 
both halves were embedded separately, and for smaller DRGs the cut was made so that one 
piece was larger (and approximately equal in size to each half of the large DRGs).
Culture Conditions—DRG hydrogel cultures used 300 μl complete media per well and 
were cultured for 5–7 days at 37°C with 5% CO2 in normoxia. The complete DRG media 
was Neurobasal media (21103049; Thermo Fisher Scientific) supplemented with 10% FBS, 
1% penicillin/streptomycin, 1% GlutaMax (35050‐061; Thermo Fisher Scientific), 1% B27 
(17–504‐044; Thermo Fisher Scientific), and 0.01% NGF (556‐NG‐100; R&D Systems, 
Minneapolis, MN).
Determination of Neuroinhibition in Uniform 3D Hydrogels
Hydrogel mixtures were prepared as described in the Base Hydrogel Composition section 
with the addition of 0.75 mg/ml laminin (344600501; R&D Systems) to enhance DRG cell 
attachment. Neuroinhibitory properties of CS biomaterials were initially assessed in uniform 
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composition 3D hydrogels. To make the hydrogels, 150 μl of the hydrogel mixture was 
pipetted into a well of a 48‐well plate, a trimmed DRG embedded, and then thermal gelation 
(30 min at 37°C) followed by UV‐photo‐initiated cross‐linking (90 s) performed (Fig. 1D). 
Samples were cultured for 5 days followed by neurite quantification (see section below).
Development and Characterization of the In Vitro Disc Innervation Culture Model
The disc innervation model featured an inner gel core to screen neuroinhibition of specific 
biomaterials (MACS‐A and MACS‐C) and an outer neuro‐permissive gel to embed the 
DRG. To create the inner hydrogel, 100 μl of gel mixture was pipetted into a well of a 96‐
well plate on top of a polypropylene sheet with handles to enable lifting the gel from the 
well after thermal gelation (20 min at 37°C). The inner gel was then transferred to a 48‐well 
plate, and 150 μl of the outer gel mixture pipetted into the adjacent area. A trimmed DRG 
was placed near the interface of the two gels, and the outer gel was thermally (20 min at 
37°C) and UV cross‐linked (90 s), followed by culture for 7 days and neurite quantification 
(Fig. 1D).
Specific enzymatic digestion of CS in the inner gel was performed to verify the mechanism 
of neuroinhibition. MAHA and MACS‐A inner gels were made as above; however, both 
thermal (30 min at 37°C) and UV cross‐linking (90 s) were performed immediately. Gels 
were washed with HBSS (BW10–543F; Thermo Fisher Scientific), incubated with 2.5U 
chondroitinase ABC (C3667; MilliporeSigma) in 2 ml HBSS plus 61 mM sodium acetate 
(W302406; MilliporeSigma) for 3 h at 37°C, and washed 9× 15 min with PBS before being 
stored in PBS at 4°C overnight. Then outer gel fabrication, DRG embedding, and culture for 
7 days were performed as with the disc innervation model, followed by neurite 
quantification.
Neurite Quantification
DRG hydrogels were fixed for 1–2 h with 4% PFA, washed with 1× PBS, blocked with 1× 
PBS containing 4% goat serum (G9023; MilliporeSigma) and 0.5% Triton X‐100 (93443; 
MilliporeSigma) for 1–2 h at room temperature, and incubated with blocking buffer 
containing anti‐Neurofilament‐H antibody (RT97; University of Iowa Developmental 
Studies Hybridoma Bank) at 0.45 μg/ml for 36 h at 4°C. Neurofilament H is a component of 
the intermediate filament of the neuronal cytoskeleton and is used to visualize neuronal 
morphology. Three 4‐h room temperature washes with PBST (1× PBS plus 0.05% Tween‐
20; BP337‐100; Thermo Fisher Scientific) were followed by a 12‐h incubation with 
blocking buffer containing goat anti‐mouse Alexafluor 488 antibody (ab150117; Abcam, 
Cambridge, MA). Finally, three 4‐h washes with PBST, 20 min incubation with 1 μg/ml 
DAPI in PBS and three 15‐min PBS washes. Imaging was performed on either (i) a confocal 
LSM 800 microscope or (ii) a cell imaging plate reader (Cytation 1; BioTek). Neurite length 
was measured by one to two blinded observers from the maximum projections of z‐stacks or 
focal plane stacks using Fiji45 Simple Neurite Tracer with 3–10 neurite traces quantified. 
Maximum radial distance of neurite extension was recorded by one to two blinded observers 
as a straight‐line measurement from the distal neurite end to the closest edge of the DRG 
body or to the edge of the inner gel as determined by transmitted light images (Fig. 1E). The 
number of neurites and groups of neurites crossing the interface from the outer gel into the 
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inner gel was counted by two blinded observers. DRGs without any discernible neurite 
growth were withdrawn from the analysis.
Statistics
All statistical analyses were performed using Prism 7 (GraphPad, San Diego, CA). For 
rheology storage and loss moduli (n = a minimum of three samples of each gel composition 
and NP tissue), metabolic activity (n = 5 experiments, triplicate wells for each group), and 
cell viability (n = 3 experiments, triplicate gels for each gel type, triplicate locations within 
each gel) significance was determined via two‐way analysis of variance (ANOVA) and 
Tukey’s multiple comparisons tests with significance threshold p < 0.05. Analysis of 
quantified neurites was performed using one‐way ANOVA with Tukey’s multiple 
comparisons tests for Figures 4, 6, and Supplementary Figure S1 and using unpaired two‐
tailed t tests for Figure 5 with p < 0.05 significance threshold for all analyses.
RESULTS
Fabrication and Characterization of Methacrylated Biomaterials
MAHA, MACS‐A, and MACS‐C exhibited consistent and robust methacrylation as assessed 
by proton NMR. Representative NMR spectra for MAHA (Fig. 2A), MACS‐A (Fig. 2B), 
and MACS‐C (Fig. 2C) are shown. Batches of MAHA consistently exhibited a 1.09 ± 0.053 
degree of methacrylation (n = 5 batches), while MACS‐A had a 1.50 ± 0.029 degree of 
methacrylation (n = 3), and MACS‐C had a 1.19 ± 0.137 degree of methacrylation (n = 2).
Mechanical Characterization of Hydrogels
The physical properties of all hydrogels were investigated using rheology (Fig. 2D). The 
storage modulus was slightly increased in gels containing MACS‐A or MACS‐C compared 
with gels containing MAHA alone (Fig. 2E). Increases in storage modulus of the same 
magnitude as observed with the CS biomaterials were reproduced in MAHA‐only gels by 
increasing the MAHA concentration (Supplementary Fig. S1F). The storage moduli of the 
base MAHA hydrogels and MAHA/MACS‐A gels were on the same order of magnitude as 
that of NP tissue explants, and the loss moduli for the gels and NP had greater variability but 
were all of a similar order of magnitude (Fig. 2E–F).
Verification of Cytocompatibility of Base Hydrogels with NP Cells
Since the intended use of these biomaterials is in disc therapeutics or replacements, the 
cytocompatibility of the biomaterials with NP cells was investigated via metabolic activity 
over time (Fig. 3A). The addition of MACS‐A or MACS‐C to the hydrogel was compared 
with a control MAHA‐only gel. There were no statistically significant differences between 
the metabolic activities of NP cells in the different gel types on the same day in culture, but 
there were significant increases in metabolic activity over time within each gel type (p < 
0.05). The ratio of living to dead cells at the end of the 7‐day culture period was quantified 
using confocal fluorescence microscopy (Fig. 3B). The mean percent live cells per region of 
interest was slightly larger in the MAHA/MACS‐A hydrogels than in the MAHA‐only or 
MAHA/MACS‐C gels (p < 0.05). Representative confocal fluorescent images of NP cells in 
hydrogels are presented with live/dead staining (Fig. 3C–E).
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Determination of Neuroinhibition in Uniform 3D Hydrogels
Degree of neuroinhibition was established by measuring the neurite length and radial 
extension from the DRG body in immunofluorescence images in which neurofilament H was 
stained to visualize the neuronal cytoskeleton morphology. Since all pre-existing neurites 
outside of the DRG were removed prior to embedding, the distance of neurite extension into 
the surrounding gel indicates whether the hydrogel is permissive or inhibitory for neurite 
growth. The images of the DRGs are presented as inverted, grayscale images of the 
fluorescent signal to allow better visualization of the fine detail of the neurites. 
Representative examples of DRGs in an MAHA hydrogel (Fig. 4A), an MAHA/MACS‐A 
hydrogel (Fig. 4B), and an MAHA/MACS‐C hydrogel (Fig. 4C) are shown. Graphs of the 
distributions of traced neurite lengths (Fig. 4D) and the radial distance of neurite extension 
from the DRG (Fig. 4E) demonstrate that MACS‐A significantly inhibited neurite growth by 
both measures (p < 0.05) and that MACS‐C significantly inhibited the maximum radial 
length of neurite extension (p < 0.05) but not traced neurite length. As the neuroinhibitory 
properties of the MACS‐A biomaterial were greater than those of MACS‐ C, MACS‐A was 
utilized for the in vitro disc innervation model.
Since the physical properties of hydrogels containing CS biomaterials exhibited increased 
hydrogel stiffness (Fig. 2), the neurite growth of DRGs was examined in gels containing 
increased concentrations of MAHA to mimic the higher storage moduli seen in MAHA/
MACS‐ A and MAHA/MACS‐C gels (Fig. 2 and Supplementary Fig. S1). These data 
demonstrate that increased MAHA concentration promoted neurite growth rather than 
inhibiting it (p < 0.05). Therefore, the neuroinhibitory properties of the CS biomaterials are 
not due to increased hydrogel stiffness.
Development and Characterization of In Vitro Disc Innervation Culture Model
Using the novel in vitro model of disc innervation, the neuroinhibitory capacity of a CS 
biomaterial was screened using an MACS‐A core (disc mimic) and an MAHA‐only outer 
gel (Fig. 1D). Representative inverted‐fluorescence images of DRGs growing across gel 
interfaces with a neuro‐permissive MAHA inner gel (Fig. 5A) and with a neuroinhibitory 
MACS‐A inner gel (Fig. 5B) are shown in grayscale to better visualize fine neurites. The 
ability of the MACS‐A biomaterial to inhibit neurite extension across the hydrogel interface 
was assessed by measuring the traced length of neurites from the border of the inner gel 
(Fig. 5C), the straight‐line/radial extension of the neurites into the inner gel (Fig. 5D), and 
the total number of neurites or groups of neurites crossing the outer/inner gel interface (Fig. 
5E). The MAHA/MACS‐A hydrogels were significantly more neuroinhibitory than MAHA‐
only hydrogels by all three measures of neurite growth (p < 0.05).
To confirm that the neuroinhibitory effects of MACS‐A were due to the CS itself, 
chondroitinase ABC enzymatic digestion of the inner gels was performed prior to DRG 
embedding. Representative images of DRGs growing across gel interfaces with a digested 
MAHA inner gel (Fig. 6A), an undigested MAHA/MACS‐A inner gel (Fig. 6B), and a 
digested MAHA/MACS‐A inner gel (Fig. 6C) are shown. Neurite growth was quantified by 
the traced length of neurites from the border of the inner gel (Fig. 6D), the straight‐line/
radial extension of the neurites into the inner gel (Fig. 6E), and the total number of neurites 
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or groups of neurites crossing the outer/inner gel interface (Fig. 6F). Neurite growth into the 
digested MAHA/MACS‐A gel was significantly greater than the growth into the undigested 
MAHA/MACS‐A gel (p < 0.05).
However, growth into the digested MAHA/MACS‐A gel was slightly less than growth into 
the MAHA gel (p < 0.05), indicating partial rescue of the MACS‐A neuroinhibition.
DISCUSSION
The novel disc innervation model presented here is a 3D hydrogel mimic of the interface 
between disc tissue and an external environment containing sensory nerves. Neuroinhibitory 
properties of biomaterials intended to treat disc degeneration and discogenic pain can be 
assessed using this model. The benefits of this 3D model over the assessment of 
neuroinhibitory properties of biomaterials in 2D culture include the control of mechanical 
properties which can influence cell phenotype44 and neurite growth,46 a more 
physiologically relevant topography in which neurites can branch in 3D, and a distinct 
interface between a neurite growth‐permissive environment and a neuroinhibitory disc 
mimic. Another variation of a 3D culture system is an organ culture model in which actual 
disc tissue is cultured adjacent to a DRG; however, an organ culture is not well suited for 
screening the neuroinhibitory properties of specific biomaterials as there is much less control 
over the contents of the disc tissue and the individual disc samples will have increased 
variability compared with a hydrogel. In future experiments, other variables relevant to the 
healthy or degenerated disc microenvironment such as pH, signaling molecules, 
inflammatory cytokines, and oxidative stress can be controlled to assess their effects on 
sensory neurons interacting with the disc.8
Currently, researchers have developed many biomaterials that restore disc mechanical 
properties/height47 or even prevent discogenic pain,26 and our in vitro model could be 
utilized with those biomaterials to determine neuroinhibitory properties and mechanisms of 
neuroinhibition. Our model could also be adapted to test engineered biomaterials for 
therapeutic uses in which neurite growth is desired such as nerve or spinal cord injury and 
regeneration. Neuromodulation and targeted innervation can have widespread clinical 
impacts for neuropathy and pain, and this model provides a valuable way to assess the 
neuromodulatory properties of biomaterials.
The in vitro disc innervation model was utilized to screen the neuroinhibitory capacity of CS 
biomaterials for future use in therapeutics for discogenic pain. The data support the disc‐like 
properties and NP cell compatibility of the biomaterials tested (Figs. 2 and 3). The hydrogel 
stiffness as indicated by the storage modulus was increased either by the incorporation of CS 
biomaterials or by increasing the concentration of MAHA, but increased MAHA 
concentrations actually promoted neurite growth so an increase in hydrogel stiffness was not 
sufficient to inhibit neurite growth (Supplementary Fig. S1). Published research 
demonstrates that neurite growth is dependent on hydrogel mechanical properties with 
substantially increased stiffness correlating with decreased nerve growth, but small 
variations (less than an order of magnitude) in stiffness do not yield significant growth 
differences.46,48 The neuroinhibitory efficacy results for biomaterials containing the two 
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types of CS that are most physiologically relevant to the disc, CS‐A and CS‐C, support the 
conclusion that CS‐A inhibits neurite growth both in a uniform gel and at an interface, while 
CS‐C is less neuroinhibitory in the context of this model (Figs. 4–6).
The greater neuroinhibitory effects of CS‐A than CS‐C on rat DRG neurons in this model 
are consistent with neuroinhibition research in neonatal mouse cerebellar granule neurons,40 
but the opposite was found in a study on embryonic rat cortical neurons in which CS‐C was 
more neuroinhibitory than CS‐A.41 These differences are likely because neurite growth 
response depends on the neuronal cell type and the local microenvironment, as the various 
CS types can bind to different neuronal receptors or sequester soluble signaling molecules.
49,50
 Thus, the incorporation of biomaterials containing CS‐A may improve the function of 
novel discogenic pain therapeutics by preventing neurite invasion from DRGs in a rat model, 
and the response of human DRG neurons to CS‐A must be confirmed prior to clinical 
translation.
In addition to the direct neuroinhibitory effects of CS‐A, there are other potential benefits to 
this molecule as a biomaterial. The vascularization of painful, degenerate discs allows 
increased immune cell infiltration which further exacerbates the inflammatory environment 
of the disc.51 The human disc CSPG aggrecan and purified CS have been demonstrated to be 
anti‐angiogenic either by direct effects on endothelial cell migration/adhesion or by 
decreasing the expression of angiogenic factors in chondrocytes.13,52 Additionally, if 
incorporated into a therapeutic that includes mesenchymal stem cells, CS biomaterials could 
prevent angiogenic and neurotrophic paracrine signaling from the stem cells.53
The demonstration of neuroinhibition by CS‐A in this model is a proof of principle and first 
step toward clinical translation. Many other steps on that path remain, such as engineering 
and validating a delivery method, animal model testing, and corroboration of neuroinhibition 
for human sensory neurons. One limitation of this model may be the use of neonatal rat 
DRGs. Neonatal DRGs were utilized for higher through‐put, but the neuroinhibitory 
properties of MACS‐A may need to be confirmed using adult rat DRGs prior to in vivo 
animal model use. Additionally, as there can be species‐specific neuromodulatory responses 
to some types of CS, neuroinhibition screening using human DRGs will be necessary prior 
to clinical translation. Other biomaterial properties such as lack of immunogenicity must 
also be confirmed prior to intervention delivery. Importantly, the neuroinhibition of CS‐A 
acts to prevent neurite growth into tissue but would not eliminate existing sensory neurites in 
a disc as a stand‐alone biomaterial. Therefore, novel therapeutics must include other 
components to cause neurite dieback/removal or inhibit sensory neurite function in order to 
treat discogenic pain.
CONCLUSIONS
The in vitro disc innervation model presented here is a screening tool that can assess 
neuroinhibition at an interface for any biomaterial that can be incorporated or immobilized 
into a hydrogel, and this has widespread potential applications both for discogenic pain 
treatments and other conditions in which control of nerve growth is needed. The initially 
Romereim et al. Page 10
J Orthop Res. Author manuscript; available in PMC 2020 May 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
screened CS biomaterials suggest that CS‐A is a strong candidate for disc therapeutics as an 
NP cell compatible means to prevent disc innervation and discogenic pain.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Schematic of experimental design and in vitro model fabrication. The structure of 
chondroitin‐4‐sulfate (CS‐A) (A) and chondroitin‐6‐sulfate (CS‐C) (B) are shown with the 
sulfate group in red. The locations of the neonatal dorsal root ganglion (DRG) harvested for 
these experiments are indicated in (C). The process of hydrogel fabrication in (D) depicts the 
differences between making a uniform composition hydrogel for either nucleus pulposus 
(NP) encapsulation or for DRG embedding versus making the in vitro disc innervation 
model with an inner gel and outer gel to embed a DRG at the hydrogel interface. Examples 
of the two different types of neurite growth quantification, traced neurite length (purple and 
green traces, green indicating the longest trace) and radial neurite extension (yellow line), 
are shown in (E) with the white line on the hydrogel interface images indicating the interface 
between the inner and outer gels. MACS‐A, methacrylated CS‐A; MACS‐C, methacrylated 
CS‐C; MAHA, methacrylated hyaluronic acid; UV, ultraviolet light. [Color figure can be 
viewed at wileyonlinelibrary.com]
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Figure 2. 
Characterization of biomaterials and hydrogels. The methacrylated biomaterials and the 
hydrogels fabricated using those biomaterials were characterized by nuclear magnetic 
resonance (NMR) to quantify the degree of biomaterial methacrylation and by rheology to 
quantify the hydrogel mechanical properties. Representative proton NMR spectra for 
methacrylated hyaluronic acid (MAHA) (A), methacrylated chondroitin sulfate A (MACS‐
A) (B), and methacrylated chondroitin sulfate C (MACS‐C) (C) are displayed. The degree of 
methacrylation was calculated as the ratio of the integral of the methacrylate peak at ~1.8 
ppm (black arrowhead) to the integral of the hyaluronic acid or chondroitin sulfate peak at 
~1.9 ppm (white arrowhead).42,44 Oscillatory rheology was performed on hydrogels 
containing the methacrylated biomaterials and collagen, with the apparatus depicted in (D). 
The increase in mean storage modulus observed with the incorporation of MACS‐A or 
MACS‐C at 10 mg/ml into gels containing MAHA at 2.25 mg/ml (n = 3 for each group) is 
graphed in (E) and compared with the storage modulus of porcine nucleus pulposus (NP) 
tissue explants (n = 5). The storage moduli of MAHA gels and NP tissue are not 
significantly different, and the storage moduli of both MAHA/MACS‐A and MAHA/
MACS‐C gels are significantly greater than those of MAHA gels or NP tissue (p < 0.05). 
The loss moduli for the gels and NP tissue are graphed in (F), and no consistent statistical 
differences were observed. Error bars are standard deviation of the mean. [Color figure can 
be viewed at wileyonlinelibrary.com]
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Figure 3. 
Cytocompatibility of hydrogels with human nucleus pulposus (NP) cells. The metabolic 
activity of human NP cells cultured in 3D hydrogels was quantified by the reduction of 
alamarBlue in culture media at Days 1, 4, and 7 in culture (n = 5 experiments, triplicate 
wells for each group) (A). There was no difference in metabolic activity between hydrogel 
types on the same day in culture, but there was an increase in metabolic activity over time 
for each hydrogel group (*p < 0.05; error bars are standard deviation of the mean). The 
viability of NP cells at the end of Day 7 (n = 3 experiments, triplicate wells for each group, 
triplicate regions of interest imaged per gel) was quantified from live/dead fluorescence 
staining and confocal microscopy (B). The mean percent of live cells (green) was greater for 
the methacrylated hyaluronic acid (MAHA)/methacrylated chondroitin‐4‐sulfate (MACS‐A) 
gels than for the MAHA and MAHA/methacrylated chondroitin‐6‐sulfate (MACS‐C) gels 
(*p < 0.05; error bars are standard deviation of the mean). Representative live/dead 
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fluorescent images from NP cells in MAHA gels (C), MAHA/MACS‐A gels (D), and 
MAHA/MACS‐C gels (E) are presented. Scale bars are 200 μm. [Color figure can be viewed 
at wileyonlinelibrary.com]
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Figure 4. 
Neurite growth inhibition by chondroitin sulfate biomaterials. Representative inverted‐
fluorescence image projections stained against neurofilament H (NF‐H) show the growth of 
neurites from the original dorsal root ganglion (DRG) cell body cluster in hydrogels 
containing 2.5 mg/ml methacrylated hyaluronic acid (MAHA) (A), 2.25 mg/ml MAHA plus 
10 mg/ml methacrylated chondroitin‐4‐sulfate (MACS‐A) (B), and 2.25 mg/ml MAHA plus 
10 mg/ml methacrylated chondroitin‐6‐sulfate (MACS‐C) (C). Scale bars are 2 mm. 
Quantified traced neurite lengths (D) and radial distance of neurite extension from the DRG 
body (E) demonstrate inhibition of neurite growth by MACS‐A via both measures and by 
MACS‐C in radial distance only (*p < 0.05; error bars are standard deviation of the mean). 
Neurite lengths are quantified in 90 DRGs across 10 experiments for MAHA gels, in 49 
DRGs in eight experiments for MAHA/MACS‐A gels, and in 26 DRGs from three 
experiments for MAHA/MACS‐C gels. Radial distance is quantified from three experiments 
with 32 DRGs in MAHA, 15 DRGs in MAHA/MACS‐A, and 22 DRGs in MAHA/MACS‐
C gels.
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Figure 5. 
Neurite growth inhibition at an interface by a chondroitin sulfate biomaterial. Representative 
inverted‐fluorescence confocal maximum intensity z‐stack projections from 
immunofluorescence staining against neurofilament H (NF‐H) show the growth of neurites 
from the original dorsal root ganglion (DRG) cell body cluster. DRGs are embedded in a 
hydrogel containing 2.5 mg/ml methacrylated hyaluronic acid (MAHA) adjacent to either a 
hydrogel containing 2.5 mg/ml MAHA (A) or adjacent to a hydrogel containing 2.25 mg/ml 
MAHA plus 10 mg/ml methacrylated chondroitin‐4‐sulfate (MACS‐A) (B). Scale bars are 
0.5 mm. Neurite lengths and radial distance are measured from the edge of the inner core gel 
(white line; determined by transmitted light microscopy). Quantification of traced neurite 
lengths (C), radial distance of neurite extension into the inner core gel (D), and the number 
of neurites/groups of neurites crossing from the outer gel to the inner gel (E) demonstrate 
inhibition of neurite growth by MACS‐A via all measures (*p < 0.05; error bars are standard 
deviation of the mean). Traced neurite lengths, radial neurite extension, and count of neurites 
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crossing the interface are quantified across three experiments from 34 DRGs with 2.5 mg/ml 
inner core MAHA gels and 32 DRGs with 2.25 mg/ml MAHA plus 10 mg/ml MACS‐A 
inner core gels.
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Figure 6. 
Rescue of chondroitin sulfate neuroinhibition by enzymatic digestion. Representative 
inverted‐fluorescence confocal z‐stack projections stained for neurofilament H (NF‐H) show 
the growth of neurites from the original dorsal root ganglion (DRG) cell body cluster. DRGs 
are embedded in a hydrogel containing 2.5 mg/ml methacrylated hyaluronic acid (MAHA) 
adjacent to a chondroitinase ABC digested hydrogel containing 2.5 mg/ml MAHA (A), an 
undigested hydrogel containing 2.25 mg/ml MAHA plus 10 mg/ml methacrylated 
chondroitin‐4‐sulfate (MACS‐A) (B), or a chondroitinase ABC digested hydrogel containing 
2.25 mg/ml MAHA plus 10 mg/ml MACS‐A (C). Scale bars are 0.5 mm. Neurite lengths 
and radial distance are measured from the edge of the inner core gel (white line(s); 
determined by transmitted light microscopy). Quantification of traced neurite lengths (D), 
radial distance of neurite extension into the inner core gel (E), and the number of neurites/
groups of neurites crossing from the outer gel to the inner gel (F) demonstrate that 
chondroitinase ABC digestion decreases the neuroinhibition of MACS‐A because all three 
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neurite growth measurements are higher in the digested MAHA/MACS‐A inner gels than in 
the undigested MAHA/MACS‐A inner gels (*p < 0.05; error bars are standard deviation of 
the mean). Neurite growth into the digested MAHA inner gels is also significantly higher 
than growth in the undigested MAHA/MACS‐A inner gels. Traced neurite lengths, radial 
neurite extension, and counts of neurites crossing the gel interface are quantified across two 
experiments from eight DRGs with digested inner core MAHA gels, seven DRGs with 
undigested inner core MAHA/MACS‐A gels, and eight DRGs with digested inner core 
MAHA gels.
Romereim et al. Page 22
J Orthop Res. Author manuscript; available in PMC 2020 May 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
